search
Back to results

Targeting Default Mode Network Dysfunction in Persons at Risk of Alzheimer's Disease With Non-invasive Techniques (NEST4AD)

Primary Purpose

Alzheimer Disease

Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
real-rTMS
sham-rTMS
Sponsored by
IRCCS Centro San Giovanni di Dio Fatebenefratelli
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Alzheimer Disease focused on measuring Alzheimer's disease, Default mode network, APOE, rTMS, connectivity

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Age: 60 years and older MMSE score > 24 Exclusion Criteria: Pathological scores in at least two standardized cognitive tests Participation in other interventional studies Known carriers of an autosomal dominant genetic mutation associated to AD Neurological, psychiatric or medical conditions not compatible with the study Exclusion Criteria for MRI and rTMS: metal implants, pace-makers, prosthetic heart valves claustrophobia history of epilepsy pregnancy

Sites / Locations

  • IRCCS Centro San Giovanni di Dio FatebenefratelliRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

real-rTMS

sham-rTMS

Arm Description

4 daily 25-minutes high-frequency rTMS sessions over one week

4 daily 25-minutes sham-rTMS sessions over one week

Outcomes

Primary Outcome Measures

Change in DMN connectivity on rs-fMRI following real-rTMS compared to sham-rTMS in APOE4 carriers
Default mode network (DMN) mean functional connectivity is assessed on resting state functional MRI. Higher values denote greater functional connectivity. A positive change at post rTMS compared to baseline represents an increase in resting-state functional connectivity.
Change in DMN connectivity on TMS-EEG following real-rTMS compared to sham-rTMS in APOE4 carriers
Single pulse TMS will be applied with concurrent EEG to derive online measures of cortical excitability and connectivity. The response in the natural frequency of the target area will index cortical excitability. Effective connectivity will be measured through amplitude and latency of TEPs.

Secondary Outcome Measures

Change in task-fMRI associative memory performance following real-rTMS compared to sham-rTMS in APOE4 carriers
Memory is assessed on task fMRI using a face-name associative paradigm

Full Information

First Posted
August 2, 2023
Last Updated
September 18, 2023
Sponsor
IRCCS Centro San Giovanni di Dio Fatebenefratelli
search

1. Study Identification

Unique Protocol Identification Number
NCT05984446
Brief Title
Targeting Default Mode Network Dysfunction in Persons at Risk of Alzheimer's Disease With Non-invasive Techniques
Acronym
NEST4AD
Official Title
Targeting Default Mode Network Dysfunction in Persons at Risk of Alzheimer's Disease With Non-invasive Techniques
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 5, 2019 (Actual)
Primary Completion Date
June 30, 2024 (Anticipated)
Study Completion Date
December 4, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
IRCCS Centro San Giovanni di Dio Fatebenefratelli

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Default mode network (DMN) dysfunction is a well-established feature of Alzheimer's Disease (AD) and is already present in preclinical stages and in subjects at risk for AD, thus offering a potential target for early intervention. Non-invasive stimulation techniques are candidate approaches to modulate network dysfunction, however interventions specifically targeting subjects at risk for AD are lacking. This project will test a non-invasive intervention to modulate the DMN in cognitively healthy older adults carrying the main genetic risk factor for AD, the APOE e4 allele. The proposal will non-invasively stimulate the DMN in at risk subjects and will assess the neuronal-cognitive effect of this approach with multimodal neuroimaging and neurophysiological techniques.
Detailed Description
Sixty-four participants will be enrolled (n=32 APOE e4 carriers, 32 non-carriers as reference group) and will undergo rTMS stimulation, TMS with concurrent electroencephalography (TMS-EEG), multimodal imaging (resting-state and task functional MRI, and diffusion tensor imaging) and cognitive assessment at baseline, after the intervention (week 1) and after 2 months. Participants will be randomized to 2 groups: active DMN stimulation (real-rTMS) or placebo (sham-rTMS). Each subject will undergo a rs-fMRI scan before the intervention to derive individualized DMN stimulation targets. rTMS will be applied over the left inferior parietal lobule node of the DMN.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer Disease
Keywords
Alzheimer's disease, Default mode network, APOE, rTMS, connectivity

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
64 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
real-rTMS
Arm Type
Experimental
Arm Description
4 daily 25-minutes high-frequency rTMS sessions over one week
Arm Title
sham-rTMS
Arm Type
Sham Comparator
Arm Description
4 daily 25-minutes sham-rTMS sessions over one week
Intervention Type
Device
Intervention Name(s)
real-rTMS
Intervention Description
Each subject will undergo 4 rTMS sessions using a 70-mm figure-eight coil (20Hz for 25 minutes). Target localization will be performed with a stereotaxic neuronavigation system.
Intervention Type
Device
Intervention Name(s)
sham-rTMS
Intervention Description
The sham condition will match the real-rTMS protocol, but a sham coil will be used.
Primary Outcome Measure Information:
Title
Change in DMN connectivity on rs-fMRI following real-rTMS compared to sham-rTMS in APOE4 carriers
Description
Default mode network (DMN) mean functional connectivity is assessed on resting state functional MRI. Higher values denote greater functional connectivity. A positive change at post rTMS compared to baseline represents an increase in resting-state functional connectivity.
Time Frame
Baseline, post rTMS (1 week)
Title
Change in DMN connectivity on TMS-EEG following real-rTMS compared to sham-rTMS in APOE4 carriers
Description
Single pulse TMS will be applied with concurrent EEG to derive online measures of cortical excitability and connectivity. The response in the natural frequency of the target area will index cortical excitability. Effective connectivity will be measured through amplitude and latency of TEPs.
Time Frame
Baseline, post rTMS (1 week)
Secondary Outcome Measure Information:
Title
Change in task-fMRI associative memory performance following real-rTMS compared to sham-rTMS in APOE4 carriers
Description
Memory is assessed on task fMRI using a face-name associative paradigm
Time Frame
Baseline, post rTMS (1 week)
Other Pre-specified Outcome Measures:
Title
Change in DMN connectivity on rs-fMRI following real-rTMS in APOE4 carriers compared to non-carriers
Description
Default mode network (DMN) mean functional connectivity is assessed on resting state functional MRI. Higher values denote greater functional connectivity. A positive change at post rTMS compared to baseline represents an increase in resting-state functional connectivity.
Time Frame
Baseline, post rTMS (1 week)
Title
Change in DMN connectivity on TMS-EEG following real-rTMS in APOE4 carriers compared to non-carriers
Description
Single pulse TMS will be applied with concurrent EEG to derive online measures of cortical excitability and connectivity. The response in the natural frequency of the target area will index cortical excitability. Effective connectivity will be measured through amplitude and latency of TEPs.
Time Frame
Baseline, post rTMS (1 week)
Title
Change in task-fMRI associative memory performance following real-rTMS in APOE4 carriers compared to non-carriers
Description
Memory is assessed on task fMRI using a face-name associative paradigm
Time Frame
Baseline, post rTMS (1 week)
Title
Change in cognition following real-rTMS in APOE4 carriers compared to non-carriers
Description
Cognition is assessed with the MMSE, the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), the Free and Cued Selective Reminding Test (FCSRT), and the preclinical Alzheimer cognitive composite (PACC) score.
Time Frame
Baseline, post rTMS (1 week)
Title
Change in cognition following real-rTMS compared to sham-rTMS in APOE4 carriers
Description
Cognition is assessed with the MMSE, the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), the Free and Cued Selective Reminding Test (FCSRT), and the preclinical Alzheimer cognitive composite (PACC) score.
Time Frame
Baseline, post rTMS (1 week)
Title
Change in cognition following real-rTMS compared to sham-rTMS in APOE4 carriers
Description
Cognition is assessed with the MMSE, the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), the Free and Cued Selective Reminding Test (FCSRT), and the preclinical Alzheimer cognitive composite (PACC) score.
Time Frame
Baseline, post rTMS (2 months)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age: 60 years and older MMSE score > 24 Exclusion Criteria: Pathological scores in at least two standardized cognitive tests Participation in other interventional studies Known carriers of an autosomal dominant genetic mutation associated to AD Neurological, psychiatric or medical conditions not compatible with the study Exclusion Criteria for MRI and rTMS: metal implants, pace-makers, prosthetic heart valves claustrophobia history of epilepsy pregnancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michela Pievani
Phone
+39 030 3501311
Email
mpievani@fatebenefratelli.eu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michela Pievani
Organizational Affiliation
IRCCS Centro San Giovanni di Dio Fatebenefratelli
Official's Role
Principal Investigator
Facility Information:
Facility Name
IRCCS Centro San Giovanni di Dio Fatebenefratelli
City
Brescia
ZIP/Postal Code
25125
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michela Pievani, PhD
Phone
+39 030 3501311
Email
mpievani@fatebenefratelli.eu
First Name & Middle Initial & Last Name & Degree
Michela Pievani, PhD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
34459405
Citation
Pievani M, Mega A, Quattrini G, Guidali G, Ferrari C, Cattaneo A, D'Aprile I, Mascaro L, Gasparotti R, Corbo D, Brignani D, Bortoletto M. Targeting Default Mode Network Dysfunction in Persons at Risk of Alzheimer's Disease with Transcranial Magnetic Stimulation (NEST4AD): Rationale and Study Design. J Alzheimers Dis. 2021;83(4):1877-1889. doi: 10.3233/JAD-210659.
Results Reference
background
PubMed Identifier
34290585
Citation
Bagattini C, Brignani D, Bonni S, Quattrini G, Gasparotti R, Pievani M. Functional Imaging to Guide Network-Based TMS Treatments: Toward a Tailored Medicine Approach in Alzheimer's Disease. Front Neurosci. 2021 Jul 5;15:687493. doi: 10.3389/fnins.2021.687493. eCollection 2021.
Results Reference
background

Learn more about this trial

Targeting Default Mode Network Dysfunction in Persons at Risk of Alzheimer's Disease With Non-invasive Techniques

We'll reach out to this number within 24 hrs